Cargando…

Artificial intelligence in ovarian cancer histopathology: a systematic review

This study evaluates the quality of published research using artificial intelligence (AI) for ovarian cancer diagnosis or prognosis using histopathology data. A systematic search of PubMed, Scopus, Web of Science, Cochrane CENTRAL, and WHO-ICTRP was conducted up to May 19, 2023. Inclusion criteria r...

Descripción completa

Detalles Bibliográficos
Autores principales: Breen, Jack, Allen, Katie, Zucker, Kieran, Adusumilli, Pratik, Scarsbrook, Andrew, Hall, Geoff, Orsi, Nicolas M., Ravikumar, Nishant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471607/
https://www.ncbi.nlm.nih.gov/pubmed/37653025
http://dx.doi.org/10.1038/s41698-023-00432-6
_version_ 1785099887591817216
author Breen, Jack
Allen, Katie
Zucker, Kieran
Adusumilli, Pratik
Scarsbrook, Andrew
Hall, Geoff
Orsi, Nicolas M.
Ravikumar, Nishant
author_facet Breen, Jack
Allen, Katie
Zucker, Kieran
Adusumilli, Pratik
Scarsbrook, Andrew
Hall, Geoff
Orsi, Nicolas M.
Ravikumar, Nishant
author_sort Breen, Jack
collection PubMed
description This study evaluates the quality of published research using artificial intelligence (AI) for ovarian cancer diagnosis or prognosis using histopathology data. A systematic search of PubMed, Scopus, Web of Science, Cochrane CENTRAL, and WHO-ICTRP was conducted up to May 19, 2023. Inclusion criteria required that AI was used for prognostic or diagnostic inferences in human ovarian cancer histopathology images. Risk of bias was assessed using PROBAST. Information about each model was tabulated and summary statistics were reported. The study was registered on PROSPERO (CRD42022334730) and PRISMA 2020 reporting guidelines were followed. Searches identified 1573 records, of which 45 were eligible for inclusion. These studies contained 80 models of interest, including 37 diagnostic models, 22 prognostic models, and 21 other diagnostically relevant models. Common tasks included treatment response prediction (11/80), malignancy status classification (10/80), stain quantification (9/80), and histological subtyping (7/80). Models were developed using 1–1375 histopathology slides from 1–776 ovarian cancer patients. A high or unclear risk of bias was found in all studies, most frequently due to limited analysis and incomplete reporting regarding participant recruitment. Limited research has been conducted on the application of AI to histopathology images for diagnostic or prognostic purposes in ovarian cancer, and none of the models have been demonstrated to be ready for real-world implementation. Key aspects to accelerate clinical translation include transparent and comprehensive reporting of data provenance and modelling approaches, and improved quantitative evaluation using cross-validation and external validations. This work was funded by the Engineering and Physical Sciences Research Council.
format Online
Article
Text
id pubmed-10471607
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104716072023-09-02 Artificial intelligence in ovarian cancer histopathology: a systematic review Breen, Jack Allen, Katie Zucker, Kieran Adusumilli, Pratik Scarsbrook, Andrew Hall, Geoff Orsi, Nicolas M. Ravikumar, Nishant NPJ Precis Oncol Review Article This study evaluates the quality of published research using artificial intelligence (AI) for ovarian cancer diagnosis or prognosis using histopathology data. A systematic search of PubMed, Scopus, Web of Science, Cochrane CENTRAL, and WHO-ICTRP was conducted up to May 19, 2023. Inclusion criteria required that AI was used for prognostic or diagnostic inferences in human ovarian cancer histopathology images. Risk of bias was assessed using PROBAST. Information about each model was tabulated and summary statistics were reported. The study was registered on PROSPERO (CRD42022334730) and PRISMA 2020 reporting guidelines were followed. Searches identified 1573 records, of which 45 were eligible for inclusion. These studies contained 80 models of interest, including 37 diagnostic models, 22 prognostic models, and 21 other diagnostically relevant models. Common tasks included treatment response prediction (11/80), malignancy status classification (10/80), stain quantification (9/80), and histological subtyping (7/80). Models were developed using 1–1375 histopathology slides from 1–776 ovarian cancer patients. A high or unclear risk of bias was found in all studies, most frequently due to limited analysis and incomplete reporting regarding participant recruitment. Limited research has been conducted on the application of AI to histopathology images for diagnostic or prognostic purposes in ovarian cancer, and none of the models have been demonstrated to be ready for real-world implementation. Key aspects to accelerate clinical translation include transparent and comprehensive reporting of data provenance and modelling approaches, and improved quantitative evaluation using cross-validation and external validations. This work was funded by the Engineering and Physical Sciences Research Council. Nature Publishing Group UK 2023-08-31 /pmc/articles/PMC10471607/ /pubmed/37653025 http://dx.doi.org/10.1038/s41698-023-00432-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Breen, Jack
Allen, Katie
Zucker, Kieran
Adusumilli, Pratik
Scarsbrook, Andrew
Hall, Geoff
Orsi, Nicolas M.
Ravikumar, Nishant
Artificial intelligence in ovarian cancer histopathology: a systematic review
title Artificial intelligence in ovarian cancer histopathology: a systematic review
title_full Artificial intelligence in ovarian cancer histopathology: a systematic review
title_fullStr Artificial intelligence in ovarian cancer histopathology: a systematic review
title_full_unstemmed Artificial intelligence in ovarian cancer histopathology: a systematic review
title_short Artificial intelligence in ovarian cancer histopathology: a systematic review
title_sort artificial intelligence in ovarian cancer histopathology: a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471607/
https://www.ncbi.nlm.nih.gov/pubmed/37653025
http://dx.doi.org/10.1038/s41698-023-00432-6
work_keys_str_mv AT breenjack artificialintelligenceinovariancancerhistopathologyasystematicreview
AT allenkatie artificialintelligenceinovariancancerhistopathologyasystematicreview
AT zuckerkieran artificialintelligenceinovariancancerhistopathologyasystematicreview
AT adusumillipratik artificialintelligenceinovariancancerhistopathologyasystematicreview
AT scarsbrookandrew artificialintelligenceinovariancancerhistopathologyasystematicreview
AT hallgeoff artificialintelligenceinovariancancerhistopathologyasystematicreview
AT orsinicolasm artificialintelligenceinovariancancerhistopathologyasystematicreview
AT ravikumarnishant artificialintelligenceinovariancancerhistopathologyasystematicreview